Piloting a new approach to the treatment of obesity using dexamphetamine

Frontiers in Endocrinology

Volumn 6, Issue FEB, 2015, Pages

  Poulton, Alison S ^a   Hibbert, Emily J ^a   Champion, Bernard L ^a   Cook, Traci L ^b   Alais, David ^c   Coulshed, David S ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b NEPEAN HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Appetite; Dexamphetamine; Dose titration; Obesity; Weight loss

Indexed keywords

DEXAMPHETAMINE;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIET; DRUG DOSE REDUCTION; ELECTROCARDIOGRAM; EXERCISE; FEMALE; HUMAN; INSOMNIA; LIFESTYLE MODIFICATION; MALE; MOUTH ULCER; OBESITY; RANDOMIZED CONTROLLED TRIAL; WEIGHT REDUCTION; XEROSTOMIA;

EID: 84926648780     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2015.00014     Document Type: Article

References (27)

1. Proietto J. Why is treating obesity so difficult? Justification for the role of bariatric surgery. Med J Aust (2011) 195:144-6.
2. Goldman RL, Canterberry M, Borckardt JJ, Madan A, Byrne TK, George MS, et al. Executive control circuitry differentiates degree of success in weight loss following gastric-bypass surgery. Obesity (Silver Spring) (2013) 21(11):2189-96. doi: 10.1002/oby.20575
3. Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Phelan S, Cato RK, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med (2005) 353:2111-20. doi:10.1056/NEJMoa050156
4. Bray GA. Lifestyle and pharmacological approaches to weight loss: efficacy and safety. J Clin Endocrinol Metab (2008) 93:S81-8. doi:10.1210/jc.2008-1294
5. Bray GA, Ryan DH. Drug treatment of the overweight patient. Gastroenterology (2007) 132:2239-52. doi:10.1053/j.gastro.2007.03.053
6. Kramer FM, Jeffery RW, Forster JL, Snell MK. Long-term follow-up of behavioral treatment for obesity: patterns of weight regain among men and women. Int J Obes (1989) 13:123-36.
7. Poulton A, Cowell CT. Slowing of growth in height and weight on stimulants: a characteristic pattern. J Paediatr Child Health (2003) 39:180-5. doi:10.1046/j.1440-1754.2003.00107.x
8. Holtkamp K, Konrad K, Müller B, Heussen N, Herpertz S, Herpertz-Dahlmann B, et al. Overweight and obesity in children with attention-deficit/hyperactivity disorder. Int J Obes (2004) 28:685-9. doi:10.1038/sj.ijo.0802623
9. Brown TE, Landgraf JM. Improvements in executive function correlate with enhanced performance and functioning and health-related quality of life: evidence from 2 large, double-blind, randomized, placebo-controlled trials in ADHD. Postgrad Med (2010) 122:42-51. doi:10.3810/pgm.2010.09.2200
10. Buitelaar JK, Casas M, Philipsen A, Kooij JJ, Ramos-Quiroga JA, Dejonckheere J, et al. Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidate. Psychol Med (2012) 42:195-204. doi:10.1017/S0033291711000845
11. Cooperative Group MTA. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry (1999) 56:1073-86. doi:10.1001/archpsyc.56.12.1073
12. Levy LD, Fleming JP, Klar D. Treatment of refractory obesity in severely obese adults following management of newly diagnosed attention deficit hyperactivity disorder. Int J Obes (2009) 33:326-34. doi:10.1038/ijo.2009.5
13. Poulton A, Briody J, McCorquodale T, Melzer E, Herrmann M, Baur LA, et al. Weight loss on stimulant medication: how does it affect body composition and bone metabolism?-A prospective longitudinal study. Int J Pediatr Endocrinol (2012) 2012:30. doi:10.1186/1687-9856-2012-30
14. Safer D, Allen R, Barr E. Depression of growth in hyperactive children on stimulant drugs. N Engl J Med (1972) 287:217-20. doi:10.1056/NEJM197208032870503
15. Kuczenski R, Segal DS. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem (1997) 68:2032-7. doi:10.1046/j.1471-4159.1997.68052032.x
16. Bernstein A, Simon F. The treatment of obesity in patients with cardiovascular disease. Angiology (1961) 12:32-7.
17. Fazekas JF, Ehrmantraut WR, Campbell KD, Negron MC. Comparative effectiveness of phenylpropanolamine and dextro amphetamine on weight reduction. J Am Med Assoc (1959) 170:1018-21. doi:10.1001/jama.1959.03010090008002
18. Hampson J, Loraine JA, Strong JA. Phenmetrazine and dexamphetamine in the management of obesity. Lancet (1960) 1:1265-7. doi:10.1016/S0140-6736(60)92250-9
19. Ray HM. The obese patient; a statistical study and analysis of symptoms, diagnosis and metabolic abnormalities; sex differences; treatment. Am J Dig Dis (1947) 14:153-62. doi:10.1007/BF03001304
20. Griffith JD, Cavanaugh J, Held J, Oates JA. Dextroamphetamine. Evaluation of psychomimetic properties in man. Arch Gen Psychiatry (1972) 26:97-100. doi:10.1001/archpsyc.1972.01750200001001
21. Kiloh LG, Brandon S. Habituation and addiction to amphetamines. Br Med J (1962) 2:40-3. doi:10.1136/bmj.2.5296.40
22. Colagiuri S, Lee CM, Colagiuri R, Magliano D, Shaw JE, Zimmet PZ, et al. The cost of overweight and obesity in Australia. Med J Aust (2010) 192:260-4.
23. Carneiro JR, Nader AC, Oliveira JE, da Silveira VG, Barroso FL. Past use of amphetamines in candidates for gastric bypass surgery in a university hospital. Obes Surg (2006) 16:31-4. doi:10.1381/096089206775222078
24. Desouza CV, Padala PR, Haynatzki G, Anzures P, Demasi C, Shivaswamy V. Role of apathy in the effectiveness of weight management programmes. Diabetes Obes Metab (2012) 14:419-23. doi:10.1111/j.1463-1326.2011.01544.x
25. Van Kammen DP, Murphy DL. Attenuation of the euphoriant and activating effects of d-and l-amphetamine by lithium carbonate treatment. Psychopharmacologia (1975) 44:215-24. doi:10.1007/BF00428897
26. Hainer V, Hainerova IA. Do we need anti-obesity drugs? Diabetes Metab Res Rev (2012) 28(Suppl 2):8-20. doi:10.1002/dmrr.2349
27. Greaves CJ, Sheppard KE, Abraham C, Hardeman W, Roden M, Evans PH, et al. Systematic review of reviews of intervention components associated with increased effectiveness in dietary and physical activity interventions. BMC Public Health (2011) 11:119. doi:10.1186/1471-2458-11-119